EUVIMEDEUVIMED entdecken
BeobachtungsstudieÜbersichtsarbeitOpen Access · CC BY 4.0

Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer

Neal Shore, Jennifer Nguyen, Barinder Kang, Amrita Sawhney, Clare Byrne, Jackson Tang, Magdaliz Gorritz, Chi-Chang Chen, Jeetvan Patel

International Journal of Clinical Oncology · 2026

DOI: 10.1007/s10147-026-03102-2 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Clinical Oncology, 2026. Verfasst von Neal Shore und 8 weiteren Autor:innen. Beteiligte Einrichtung: START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. nshore@auclinics.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Taxoids, Bridged-Ring Compounds, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic castration-resistant prostate cancer (mCRPC) treatment commonly includes first-line (1L) androgen receptor pathway inhibitors (ARPIs) followed by second-line (2L) taxane-based chemotherapy. Adverse events (AEs) may lead to early taxane discontinuation, which can negatively affect outcomes and costs. This retrospective observational study assessed real-world outcomes, AEs, and costs of 2L taxane therapy by number of cycles among patients with mCRPC previously treated with a 1L ARPI; outcomes were compared with patients receiving 2L ARPI.

Methods

Overall survival (OS; overall and by number of taxane cycles received) was determined for 2L taxane and compared with 2L ARPI using the Flatiron Health electronic health record database (Jul 1, 2012, to Jun 30, 2020). Taxane-related AEs and associated costs were estimated using the IQVIA PharMetrics® Plus claims database (Jan 1, 2013, to Aug 31, 2021).

Results

Overall, 2L ARPI ( n = 473) vs. taxane ( n = 214) was associated with longer median OS (15.4 vs. 13.6 months). Patients receiving > 8 ( n = 48) vs. ≤ 8 taxane cycles ( n = 166) had longer median OS (18.4 vs. 11.9 months; p = 0.006). Patients receiving > 8 vs. ≤ 8 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334).

Conclusion

Patients who received > 8 cycles of 2L taxane had longer observed survival. However, these results are subject to selection bias and immortal time bias. Prospective or time-adjusted analyses are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantTaxoidsBridged-Ring CompoundsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedRetrospective StudiesMiddle AgedNeoplasm MetastasisAged, 80 and overTreatment OutcomeAndrogen Receptor Antagonists

Stichwörter der Autor:innen

Castration resistanceCostMetastaticProstate cancerTaxane-based chemotherapy

Substanzen

TaxoidstaxaneBridged-Ring CompoundsAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. nshore@auclinics.com.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Asclepius Analytics, New York, NY, USA.
  • IQVIA, Wayne, PA, USA.

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Shore, N., Nguyen, J., Kang, B., Sawhney, A., Byrne, C., Tang, J., Gorritz, M., Chen, C. C., & Patel, J. (2026). Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03102-2

Vancouver

Shore N, Nguyen J, Kang B, Sawhney A, Byrne C, Tang J, et al. Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03102-2

BibTeX
@article{Shore2026,
  author = {Shore, Neal and Nguyen, Jennifer and Kang, Barinder and Sawhney, Amrita and Byrne, Clare and Tang, Jackson and Gorritz, Magdaliz and Chen, Chi-Chang and Patel, Jeetvan},
  title = {Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1007/s10147-026-03102-2}
}
Kostenlos starten →